Arbutus Biopharma: IM-PROVE I Clinical Trial Demonstrated Undetectable HBsAg in 33% of Patients >ABUS
Arbutus Biopharma: IM-PROVE I Clinical Trial Demonstrated Undetectable HBsAg in 33% of Patients >ABUS
Arbutus Biopharma:Im-PROVE I臨床試驗顯示33%的患者HBsAg檢測結果不可檢測>ABUS
Unity Software(U.US) reported fourth-quarter financial results after the market close on Monday. Here's a rundown of the report.Q4 Earnings: Unity said fourth-quarter revenue increased 35% year-over-year to $609 million, beating the consensus estimate of $562.71 million. The company reported a quarterly loss of 66 cents per share.
登入免費觀看全文
登入/註冊